News

The Phase 1 dose-ranging study expects to investigate ACY-1215 alone and in conjunction with bortezomib (Velcade) and dexamethasone. Following identification of optimal combination dosing in Phase 1, the

Fibroblast Growth Factor 21 (FGF-21) protein is indicated for use in treating type 2 diabetes, and the Relaxin hormone, for treating heart failure. The agreement enables Ambrx to

The company’s Rivastigmine Tartrate Capsules are the generic version of Novartis’ Exelon Capsules. Exelon is a cholinesterase inhibitor which helps in treating mild to moderate dementia in patients

The lawsuit alleges that under an agreement signed with Watson Pharmaceuticals, Amphastar has given right to market, sell and distribute Enoxaparin Sodium Injection in the US, infringing Momenta’s

Developed by ImmunoGen, IMGN529 is indicated as a treatment for B-cell malignancies including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). ImmunoGen president and CEO Daniel Junius said

The 52-week analysis showed that saxagliptin tablet added to insulin (with or without metformin) reduced blood sugar levels (HbA1c) in adult patients with type 2 diabetes compared to

In the first order, the Chinese company will purchase Mimetic Ligand affinity adsorbent, developed and manufactured by the UK-based subsidiary of ProMetic, to manufacture a biosimilar product in

Most recently, Celniker worked as the president and CEO of Taligen Therapeutics. Before joining Taligen, Celniker was global head of biologics at Novartis, where she oversaw the biologics

The deal allows Mullis to become the chief scientific officer and Charles Roberts, CEO of Loxbridge, takes on the role of president of Altermune for the initial developmental